Measles
MICROBIOLOGY
- Measles virus (Morbillivirus hominis) is an enveloped, negative-sense, single-stranded RNA virus in the family Paramyxoviridae.
- Related to other morbilliviruses infecting animals, including rinderpest virus, peste des petits ruminants virus, canine distemper virus and dolphin morbillivirus.
- Measles virus (MV), also known as rubeola, is a respiratory agent with subsequent viremia.
- Related viruses in the order Mononegavirales:
- Human metapneumovirus
- Hendra virus
- RSV
- Parainfluenza
- Nipah virus, a cause of encephalitis.
CLINICAL
- Measles (rubeola) was among the most contagious and common childhood viral infections before widespread vaccination.
- Epidemiology: Remains a global problem, and eradication is difficult despite WHO efforts for this vaccine-preventable infection, particularly in lower-resource countries, due to multiple factors including maintaining a cold chain for vaccines, insufficient two-dose coverage, conflict, population displacement, vaccine hesitancy, and health-system disruptions.
- WHO recorded 411,913 reported cases worldwide in 2025, compared with 476,412 in 2024.
- Surveillance substantially underestimates disease burden. WHO estimated approximately 11 million infections and 95,000 measles-related deaths globally in 2024.
- Global first-dose measles vaccine coverage was 84% in 2025.
- Global accounting on the WHO Measles dashboard
- U.S.
- 2,289 cases were reported in 2025.
- As of October 29, 2026, CDC reported 4,852 confirmed cases, 96% associated with outbreaks.
- 2026 measles deaths were reported as 4 by the CDC, but state health departments have the number higher at 7 (1 in NY, 6 in PA).
- Transmission predominantly occurs in communities with inadequate vaccination coverage, often following importation.
- Updated surveillance is available on the CDC outbreak website.
- WHO recorded 411,913 reported cases worldwide in 2025, compared with 476,412 in 2024.
- Clinical:
- Suspect measles in patients with fever, cough, coryza, conjunctivitis, and a generalized maculopapular rash [Fig 1], particularly with compatible travel, exposure, or incomplete vaccination.
- Koplik spots strongly support the diagnosis but are not always present.
- Modified measles in previously vaccinated individuals may produce atypical or absent clinical findings.
- Incubation: typically 10-12 days following exposure; the first symptoms are high fever and flu-like symptoms, cough and coryza.
- Koplik spots: appear 2-3 days after the onset of symptoms, and occur on the inside of the mouth as tiny, bluish-white spots surrounded by erythema on the buccal mucosa [Fig. 2]. It may precede rash onset and is pathognomonic of measles.
- Rash: typically 3-5 days after illness onset, a generalized maculopapular rash that begins on the face and spreads downward, becoming large, confluent blotches over the entire body [Fig. 3].
- Fever commonly peaks around rash onset and usually subsides over the following 2–3 days. Persistent or recurrent fever warrants assessment for complications.
- Patients may also experience diarrhea, vomiting, lymphadenopathy, abdominal pain, pharyngitis, splenomegaly, leukopenia, and thrombocytopenia.
- The entire acute illness lasts up to 10-14 days. Patients usually become afebrile by 2-3 days after the rash appears.
- If the fever persists, suspect a secondary bacterial infection.
- Suspect measles in patients with fever, cough, coryza, conjunctivitis, and a generalized maculopapular rash [Fig 1], particularly with compatible travel, exposure, or incomplete vaccination.
- Modified measles syndrome: measles in persons with preexisting immunity, including prior vaccination or immune globulin administration.
- If due to secondary vaccine failure, may have mild symptoms with only rash and no fever or mild respiratory complaints.
- These infected people tend to pose a lower transmission risk.
- If due to primary vaccine failure, they tend to behave like the unimmunized.
- If due to secondary vaccine failure, may have mild symptoms with only rash and no fever or mild respiratory complaints.
- Atypical measles: resulted from exposure to the measles virus in those who received the killed measles vaccine between 1963 and 1967 before it was withdrawn from the market.
- Presented with hemorrhagic petechial rash, severe disease with high fever and significant pneumonia.
- Essentially not reported nowadays, given the time since primary vaccination or MMR booster.
- Diagnosis:
- Clinical:
- Clinical suspicion is essential, but suspected measles should be confirmed by appropriate laboratory testing and promptly reported.
- Diagnosis is raised based on acute febrile illness, characteristic rash and/or Koplik spots (irregular red spots with tiny blue-white specks on the buccal/lingual mucosa) in a patient with residence or travel within an endemic country or recent exposure to an index or secondary case.
- Clinical suspicion is essential, but suspected measles should be confirmed by appropriate laboratory testing and promptly reported.
- RT-PCR:
- Preferred approach using nasopharyngeal or throat swabs, obtained as soon as possible, ideally within 0–3 days after rash onset.
- Viral RNA may remain detectable for up to 10 days.
- Concomitant urine sampling can increase sensitivity.
- Viral genotyping can distinguish wild-type measles infection from a vaccine-associated rash. This distinction can be helpful when an exposed individual has recently received MMR.
- Negative testing in a previously vaccinated patient with high clinical suspicion may warrant evaluation by a public health reference laboratory.
- Serology:
- Obtain measles IgM with RT-PCR.
- IgM may be negative during the first 72 hours after rash onset; repeat testing ≥72 hours after rash onset if initially negative and suspicion persists.
- False-positive IgM results occur, particularly in low-prevalence settings.
- Measles IgG: Useful for assessing immunity, not generally for diagnosing acute infection from a single specimen.
- IgG avidity testing may help distinguish primary from secondary vaccine failure.
- Obtain measles IgM with RT-PCR.
- Culture: tissue/secretions may be cultured for viruses and/or identified by IFA. Not routinely obtained.
- Public health: Immediately report suspected cases and coordinate testing with local or state health departments. Do not await confirmation before implementing airborne precautions.
- Clinical:
- Secondary complications: occur during the post-infectious immunosuppressive period caused by the primary viral infection, which may last months to years.
- From symptom onset
- 5-30 days: pneumonia, giant cell pneumonia (rare, multinucleated giant cells within alveoli), pneumonitis
- Pneumonia is among the most common complications, with a higher risk in lower- and middle-income countries.
- 8-30 days: chronic diarrhea, conjunctivitis, corneal ulceration, keratitis, otitis media
- 30 days-1 year: blindness, other secondary infections, pneumonia, malnutrition
- 5-30 days: pneumonia, giant cell pneumonia (rare, multinucleated giant cells within alveoli), pneumonitis
- Otitis media, bronchopneumonia, croup, diarrhea and bronchitis.
- Most common in children < 5 yrs, adults > 20 yrs.
- Many deaths from measles occur in malnourished children, succumbing to pneumonia or diarrhea.
- In low-resource countries, tuberculosis, viral infections (adenovirus, herpesviruses), and other bacterial infections (S. aureus, Klebsiella, Pseudomonas).
- Pregnancy: miscarriage, preterm delivery
- Neurological complications: among the most feared.
- Acute measles encephalitis:
- Occurs in approximately 1 per 1,000 measles cases; may involve direct viral CNS infection or immune-mediated inflammation. Associated with substantial mortality and permanent neurological sequelae.
- Acute postinfectious encephalomyelitis (ADEM):
- Immune-mediated demyelinating syndrome occurring days to weeks after measles, typically with encephalopathy and multifocal neurological deficits.
- MRI may demonstrate multifocal white-matter abnormalities.
- Treatment is individualized; corticosteroids and/or IVIG have been used, but measles-specific controlled evidence is lacking.
- Measles inclusion-body encephalitis (MIBE):
- Rare, progressive encephalitis primarily affecting severely immunocompromised individuals, usually weeks to months after infection. CSF findings may be nondiagnostic, and brain tissue may be required for confirmation. Prognosis is poor.
- Subacute sclerosing panencephalitis (SSPE):
- Progressive, usually fatal CNS disease developing years after wild-type measles infection by aberrant ongoing viral replication, particularly when acquired in early childhood.
- Estimated frequency is approximately 7–11 per 100,000 measles cases, with higher risk after infection before age two.
- Diagnostic findings include:
- EEG: characteristic periodic spikes (Radermecker complex)
- Brain biopsy: eosinophilic inclusion bodies
- CSF: high measles IgG titers
- Diagnostic findings include:
- Characteristic findings include progressive cognitive and motor dysfunction, myoclonus, periodic EEG complexes, and intrathecal measles-specific antibody production. No reliably effective treatment is established.
- Acute measles encephalitis:
- From symptom onset
SITES OF INFECTION
- Mucocutaneous/systemic: characteristic disease progression starts with a prodrome of fever, cough, coryza, and conjunctivitis, followed by a flat macular rash that fuses into blotches, first over face/hairline, then spreading cephalocaudally to trunk and extremities.
- Pulmonary: pneumonitis (giant-cell pneumonia) during primary measles virus infection.
- Atypical measles: now rare or nonexistent; pneumonitis as the hallmark with a hypersensitivity-like reaction in recipients of killed measles vaccine (given in the 1960s-1970s) exposed to native measles.
- CNS:
- Acute primary measles encephalitis:
- Occurs during acute infection, usually around rash onset, reflecting direct viral CNS infection.
- May cause severe encephalopathy, seizures, and permanent neurological sequelae.
- Acute postinfectious encephalomyelitis (ADEM):
- Immune-mediated demyelinating syndrome that develops days to weeks after measles, often after rash resolution.
- MRI typically demonstrates multifocal white-matter abnormalities.
- CSF measles PCR is usually negative.
- Measles inclusion-body encephalitis (MIBE):
- Rare, progressive CNS infection occurring weeks to months after measles, predominantly in severely immunocompromised patients.
- CSF findings may be nondiagnostic.
- MV RNA may be detected in brain biopsies.
- Brain tissue testing may establish the diagnosis.
- Prognosis is poor.
- Subacute sclerosing panencephalitis (SSPE):
- Delayed, progressive, usually fatal encephalitis caused by persistent, altered measles virus, typically developing 7–10 years or more after wild-type infection.
- Characterized by cognitive and behavioral deterioration, myoclonus, seizures, and progressive neurological disability.
- See Neurological Complications under Clinical for incidence, diagnostic findings, and outcomes.
- Acute primary measles encephalitis:
TREATMENT
General
- Report suspected measles cases to the local or state health department ASAP. Do not wait for diagnostic confirmation.
- Immediately report suspected measles and institute airborne precautions before diagnostic confirmation. See Prevention below for isolation duration, healthcare respiratory protection, and postexposure management.
- If at home, isolation is necessary:
- Consider patients infectious from 4 days before rash onset until 4 days after rash onset.
- Detailed CDC guidance on measles prevention, post-exposure management, serologic testing, healthcare personnel recommendations, and outbreak investigation is available separately in the 2013 MMWR.
Children
- Most otherwise healthy children can be managed as outpatients with supportive care and supervised vitamin A treatment
- Vitamin A — Pediatric measles (AAP 2026)
- Age under 6 months: 50,000 IU orally once daily for 2 days.
- Age 6–11 months: 100,000 IU orally once daily for 2 days.
- Age ≥12 months: 200,000 IU orally once daily for 2 days.
- Vitamin A deficiency or ocular manifestations: In children with clinical evidence of vitamin A deficiency, including ocular manifestations, give a third age-specific dose 2–6 weeks after the initial course.
- Excessive or repeated dosing may cause hepatotoxicity, intracranial hypertension, and other serious adverse effects. Routine high-dose treatment in adults, particularly during pregnancy, is not established.
- NOTE: Vitamin A supplementation should not be considered an alternative to measles immunization for prevention.
Adults
- Supportive care.
- The infection tends to be more severe than in pediatric populations.
- Ribavirin: No antiviral therapy has established efficacy for measles, and ribavirin is not FDA-approved for this indication.
- IV or aerosolized ribavirin has been used in selected patients with severe pneumonitis or encephalitis, particularly in immunosuppressed patients, but evidence is limited to case reports and small uncontrolled series.
- Routine use is not recommended; exceptional use requires specialist consultation and consideration of toxicity and access limitations.\
- IV ribavirin in the U.S. requires an emergency investigational new drug pathway. CDC specifically notes that IV ribavirin is available only through an Emergency IND application.
- Vitamin A supplementation:
- No established U.S. recommendation for routine high-dose vitamin A supplementation in adults with measles.
- WHO materials also address adult supplementation, although recommendations differ by source.
- Consider nutritional status and local guidance; avoid high-dose vitamin A during pregnancy because of teratogenicity concerns.
Neurological disease
- Acute post-measles encephalitis:
- Management is primarily supportive
- Corticosteroids and/or IVIG have been used in selected post-infectious inflammatory cases, but evidence is limited, and specialist consultation is recommended.
- It may be difficult to distinguish from primary measles virus encephalitis, wherein only supportive care is recommended.
- Management is primarily supportive
- Subacute sclerosing panencephalitis (SSPE)
- Remdesivir (investigational):
- Demonstrates potent in vitro activity against measles virus. In a rhesus macaque model of acute measles, remdesivir transiently suppressed viral replication but did not improve clinical outcomes or prevent viral rebound after treatment discontinuation.[6]
- Two human reports describe compassionate-use treatment for SSPE, with transient neurological improvement or possible stabilization but no established sustained efficacy.
- Remdesivir is not recommended for routine acute measles treatment or postexposure prophylaxis.
- Its use for SSPE remains experimental, without an established dosing regimen.[5][2]
- Demonstrates potent in vitro activity against measles virus. In a rhesus macaque model of acute measles, remdesivir transiently suppressed viral replication but did not improve clinical outcomes or prevent viral rebound after treatment discontinuation.[6]
- Remdesivir (investigational):
Prevention
- Infection control:
- Immediately isolate suspected measles using airborne precautions; notify infection prevention and public health authorities without waiting for laboratory confirmation.
- Infectious period in immunocompetent patients: 4 days before through 4 days after rash onset (rash onset = day 0).
- Severely immunocompromised patients may shed virus for longer and should remain in airborne isolation throughout illness.
- Measles virus can remain infectious in shared air for up to 2 hours after an infectious patient leaves.
- Use a fit-tested N95 respirator or equivalent protection for healthcare personnel, regardless of vaccination status.
- Identify suspected cases and mask them before they enter common clinical areas whenever possible.
- Measles Postexposure Prophylaxis (PEP) and Early Vaccination — 2026
- Give MMR as soon as possible, within 72 hours of initial exposure, for vaccine-eligible contacts. Administer IG within six days.
- Neither intervention guarantees prevention, but both may prevent or modify measles.
- Coordinate PEP with local public health authorities; IG is intended for selected vulnerable exposed individuals, not mass outbreak control.
- Measles PEP uses standard pooled human immune globulin (IG), not a measles-specific hyperimmune preparation. The choice is between intramuscular IG (IGIM) and conventional intravenous IG (IVIG), depending on age, weight, pregnancy, and immune status.
- IG is prioritized for significant exposures, particularly household, childcare, and other prolonged close-contact settings. It is not automatically administered for every potential exposure.
- Products:
- GamaSTAN (U.S. IGIM) is administered as a deep IM injection; large doses may require multiple injection sites: 0.5 mL/kg, maximum 15 mL
- The GamaSTAN package insert retains a historical measles PEP dose of 0.25 mL/kg for susceptible contacts, whereas current CDC guidance recommends 0.5 mL/kg; use the higher dosing CDC recommendation.
- Do not give IV; only IM.
- When IG prophylaxis is indicated, individuals weighing ≥30 kg should receive IVIG rather than volume-limited IGIM.
- Standard pooled IVIG is given by IV infusion by trained clinical personnel: 400 mg/kg, generally a single infusion
- GamaSTAN (U.S. IGIM) is administered as a deep IM injection; large doses may require multiple injection sites: 0.5 mL/kg, maximum 15 mL
- IG provides temporary protection for approximately 3–4 weeks,
- Patients receiving regular IVIG may not require additional measles PEP if they received ≥400 mg/kg within three weeks before exposure; verify timing and dose with the treating specialist and public health authorities.
- Do not administer MMR and IG simultaneously because passive antibody interferes with the live vaccine response. If IG has been administered, defer subsequent MMR vaccination for six months after IGIM or eight months after IVIG at the PEP doses described.
- Postexposure monitoring: Immune globulin may prolong measles incubation.
- Monitor exposed recipients through day 28 after their last exposure rather than the usual 21 days. Quarantine or work-exclusion requirements should be determined with public health authorities and may also be extended to 28 days.
U.S. PEP recommendations from CDC, including the 2026 measles IG guidance; WHO routine and supplementary vaccination recommendationsRecipient/setting (At risk groups)
Recommended intervention
Timing
Practical considerations
Susceptible, immunocompetent ≥12 months
MMR vaccine, 0.5 mL SC/IM depending on product
Within 72 hours of exposure
IG generally not needed; consider only in selected high-risk exposures
Infants <6 months
IGIM 0.5 mL/kg (maximum 15 mL)
Within 6 days
MMR not recommended at this age
Infants 6–11 months
MMR 0.5 mL if ≤72 hours; IGIM 0.5 mL/kg if later or vaccine unsuitable.
MMR ≤72 hours; IGIM ≤6 days (IGIM after 72 hours is prioritized for significant exposure, rather than automatic for every exposure)
Early MMR does not count toward the two-dose U.S. routine series
Susceptible pregnant patients
IVIG 400 mg/kg
Within 6 days
Live MMR contraindicated during pregnancy
Severely immunocompromised patients
IVIG 400 mg/kg
Within 6 days
PEP may be indicated regardless of previous MMR vaccination
- Give MMR as soon as possible, within 72 hours of initial exposure, for vaccine-eligible contacts. Administer IG within six days.
- Immunization
- See measles vaccine module for vaccine-specific recommendations and schedules, US and global.
OTHER INFORMATION
- Measles had been considered eliminated in the U.S. (2000) as few cases were imported; however, two-plus decades have seen numerous outbreaks in the non-immune, placing this status in 2026 as at risk.
- Measles generally requires approximately 95% two-dose vaccination coverage to prevent sustained transmission, although local susceptibility patterns are critical.
- Clinical tips:
- Recognize before the rash:
- Fever, cough, coryza, and conjunctivitis may precede the exanthem by several days.
- Koplik spots are highly characteristic but are not always present.
- Isolate before testing: Measles is transmissible approximately four days before rash onset.
- Suspected cases require immediate airborne precautions and public health notification; virus may remain infectious in shared air for up to two hours.
- Vaccination does not completely exclude measles:
- Breakthrough cases may have mild or atypical symptoms, including absent fever or an atypical rash. Infection-control precautions remain necessary.
- Order PCR and IgM together:
- Obtain a respiratory swab promptly.
- An IgM collected during the first 72 hours after rash onset may be falsely negative; false-positive IgM results also occur.
- Watch for atypical infection in immunocompromised patients:
- Rash may be absent, viral shedding may be prolonged, and severe pneumonitis or encephalitis can develop.
- Maintain airborne isolation throughout illness.
- Assess for secondary infection:
- Persistent or recurrent fever, worsening respiratory symptoms, hypoxemia, or focal findings should prompt evaluation for bacterial pneumonia or other complications. Measles-associated immune amnesia can increase subsequent infection risk.
- Vitamin A is treatment, not prevention:
- Use supervised age-specific dosing in children with measles.
- Excess supplementation can cause serious toxicity and does not replace vaccination.
- Watch for delayed neurological disease:
- SSPE may develop years after apparent recovery, especially after infection in infancy or early childhood.
- Progressive cognitive or behavioral changes, myoclonus, and seizures warrant evaluation.
- No proven antiviral treatment:
- Supportive management remains standard. Ribavirin has only limited, uncontrolled evidence and should not be used routinely.
- Recognize before the rash:
- Vaccine immunity: MMR effectiveness against measles is approximately 93% after one dose and 97% after two doses; protection is generally durable.
- Conversion failure may also be linked to inadequate vaccine refrigeration, which can reduce potency.
- In mumps outbreaks, the third dose of MMR vaccine is now recommended for those at increased risk, but this is not a recommendation for measles.
- Immune amnesia:
- Measles infection can deplete preexisting memory B- and T-cell responses, reducing protection against infections for which immunity was previously acquired.
- Increased susceptibility to secondary bacterial and viral infections may persist for months to years after recovery.
- Reductions of approximately 11%–73% in the preexisting antibody repertoire occur following natural measles infection.[9]
- Measles vaccination prevents this complication rather than causing it.
- Large studies have found no causal association between MMR vaccination and autism.
Basis for recommendation
- Do LAH, Mulholland K. Measles 2025. N Engl J Med. 2025;393(24):2447-2458. [PMID:40561553]
Comment: This narrative review covers clinical presentations, complications and current recommendations for measles care and prevention.
References
- Gebara A, Homeidat M, Keadan T, et al. Remdesivir Treatment Outcomes of Subacute Sclerosing Panencephalitis Presenting with Macular Necrotizing Retinitis: A Case Report. Ocul Immunol Inflamm. 2025;33(8):1873-1876. [PMID:40531784]
Comment: A 31-year-old woman with SSPE-associated necrotizing retinitis received remdesivir, IVIG, and subsequently intrathecal interferon-α. Retinal necrosis progressed despite treatment, although neurological and contralateral ocular disease appeared relatively stable at one year. The combination of treatments prevents attribution of benefit specifically to remdesivir.
- Leung J, Munir NA, Mathis AD, et al. The Effects of Vaccination Status and Age on Clinical Characteristics and Severity of Measles Cases in the United States in the Postelimination Era, 2001-2022. Clin Infect Dis. 2025;80(3):663-672. [PMID:39271123]
Comment: Analysis of 4,056 U.S. measles cases (2001–2022) shows a less typical presentation and reduced severity among vaccinated individuals. Highlights the issue of considering modified measles in previously vaccinated patients and recognizing that vaccination history alone does not exclude infection.
- Brady AM, El-Badry E, Padron-Regalado E, et al. Serosurveillance for Measles and Rubella. Vaccines (Basel). 2024;12(7). [PMID:39066453]
Comment: Ten-year look (2014-2024) of published studies of < 20% publish titers as part of their protocol. Another caveat when looking at such data is that there is considerable heterogeneity of assays which make comparisons challenging.
- Schmitz KS, Handrejk K, Liepina L, et al. Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments. J Virol. 2024;98(3):e0187423. [PMID:38329336]
Comment: A five-year-old with SSPE received three 14-day courses of intravenous remdesivir. Neurological improvement, including reduced myoclonic seizures and improved responsiveness, occurred after the first two courses. The third course offered no apparent benefit, and the patient ultimately died. Postmortem testing demonstrated persistent measles infection in brain tissue without evidence of remdesivir resistance.
- Peart Akindele NA, Katamoni LD, Brockhurst J, et al. Effect of remdesivir post-exposure prophylaxis and treatment on pathogenesis of measles in rhesus macaques. Sci Rep. 2023;13(1):6463. [PMID:37081035]
Comment: Intravenous remdesivir administered for 12 days beginning either three days after infection or at clinical disease onset (day 11) did not improve clinical outcomes. Early administration reduced viral RNA transiently, but infectious virus persisted and viral RNA rebounded after discontinuation.
- Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet. 2022;399(10325):678-690. [PMID:35093206]
Comment: Comprehensive review of measles virology, epidemiology, pathogenesis, clinical manifestations, complications, laboratory diagnosis, and prevention. Particularly useful for global disease burden and the diversity of clinical presentations.
- Lo Vecchio A, Krzysztofiak A, Montagnani C, et al. Complications and risk factors for severe outcome in children with measles. Arch Dis Child. 2020;105(9):896-899. [PMID:30636224]
Comment: Somewhat surprisingly, this study from Italy did not find an age relationship; instead, it found CRP to be a risk factor for complications. This may well contrast with what is seen in children in low-resource settings, especially if malnourished.
- Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366(6465):599-606. [PMID:31672891]
Comment: Demonstrated reductions of 11%–73% in the preexisting pathogen-specific antibody repertoire following natural measles infection, providing mechanistic evidence for measles-associated immune amnesia and increased susceptibility to subsequent infections.
- Wendorf KA, Winter K, Zipprich J, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clin Infect Dis. 2017;65(2):226-232. [PMID:28387784]
Comment: Report from California of 17 SSPE cases, particularly in unvaccinated children who acquired native infection in infancy. The median age of diagnosis = is 12 years, with a latency period estimated at 9.5 years (range 2.5 to 34 years). The authors argue that infants, especially before immunization, should not travel to regions endemic for measles, and that early immunization should be considered during months 6-11.
- Fisher DL, Defres S, Solomon T. Measles-induced encephalitis. QJM. 2015;108(3):177-82. [PMID:24865261]
Comment: Helpful survey article reviewing the four major types of measles virus-related encephalitis.
- Scott P, Moss WJ, Gilani Z, et al. Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. J Infect Dis. 2011;204 Suppl 1:S164-78. [PMID:21666158]
Comment: Immunization appears generally safe in HIV-infected children upon review of 39 studies, but the authors cite the data as limited.
- Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis. 1994;19(3):454-62. [PMID:7811865]
Comment: Small, uncontrolled series of six adults with severe measles pneumonitis treated with IV ribavirin. Five survived, but without a control group, efficacy cannot be established; ribavirin remains an investigational treatment for severe measles.
Rating: Important - Kaplan LJ, Daum RS, Smaron M, et al. Severe measles in immunocompromised patients. JAMA. 1992;267(9):1237-41. [PMID:1538561]
Comment: Historical series documenting severe measles in immunocompromised patients, including atypical or absent rash and severe pneumonitis. Serologic responses may be unreliable; contemporary diagnosis should emphasize molecular testing rather than the culture or immunofluorescence methods used historically.
- Gremillion DH, Crawford GE. Measles pneumonia in young adults. An analysis of 106 cases. Am J Med. 1981;71(4):539-42. [PMID:7282741]
Comment: Atypical measles occurred in recipients of the formalin-inactivated measles vaccine [1963-1967] and subsequently exposed to wild-type measles virus. Sx severity is worse in atypical measles. Instead of starting at the head and spreading down the body, the rash of atypical measles spreads centripetally, not only maculopapular but also hemorrhagic, vesicular, or urticarial. Coryza, conjunctivitis, and Koplik spots were unusual in atypical measles. However, interstitial pneumonia is a prominent feature of atypical measles, along with pleural effusions, extremity edema, hepatitis, and hyperesthesia. Has been confused with RMSF.
- AAP. Red Book. Measles. 2024-2027
Comment: Current pediatric guidance addressing clinical presentation, complications, diagnosis, management, infection control, and postexposure prophylaxis. Supports age-specific vitamin A treatment and its use as an adjunct to supportive care.
- WHO. Measles fact sheet. July 15, 2026.
Comment: Current global measles epidemiology, including an estimated 95,000 deaths in 2024, 84% global first-dose vaccine coverage in 2025, and the importance of sustained two-dose coverage to prevent outbreaks.
- CDC. Laboratory Support for Surveillance of Vaccine-Preventable Diseases. Chapter 22, 2026
Comment: Recommends concurrent respiratory RT-PCR and measles IgM testing; optimal specimen collection early after rash onset; the limitations of early IgM testing; and using molecular testing to distinguish vaccine-associated rash from wild-type infection.
- CDC. Interim Infection Prevention and Control Recommendations for Measles in Healthcare Settings. Aug 25, 2025
Comment: Current recommendations for airborne isolation, respiratory protection for healthcare personnel regardless of vaccination status, and management of potentially prolonged viral shedding in immunocompromised patients.
Media
Measles rash
Source: CDC
Koplik spots
Source: CDC
Measles d3 rash
Source: CDC

Johns Hopkins ABX Guide

